Literature DB >> 12964018

Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation.

Yasuhiro Ogawa1, Toshiaki Takahashi, Toshihiro Kobayashi, Shinji Kariya, Akihito Nishioka, Hiroo Mizobuchi, Masataka Noguchi, Shinji Hamasato, Toshikazu Tani, Harumichi Seguchi, Shoji Yoshida, Hiroshi Sonobe.   

Abstract

In our previous study, we examined reactive oxygen species (ROS) formation in T lymphocytes following 5 Gy of irradiation. Using a CCD camera system, we monitored fluorescence in T lymphocytes loaded with the succinimidyl ester of Dichlorodihydrofluorescein diacetate (H2DCFDA), which is non-fluorescent until oxidized by ROS. We found that ROS formation occurred immediately after irradiation, continued for several hours, and resulted in oxidative DNA damage. Therefore, the origin of the hyper-radiosensitivity of T lymphocytes seemed to be the high production of ROS in the mitochondrial DNA following irradiation. In this study, we examined radiation-induced ROS formation, oxidative DNA damage, early apoptotic changes, and mitochondrial membrane dysfunction in the human osteosarcoma cell line HS-Os-1, which was established from an osteoblastic tumor that arose in the left humerus of an 11-year-old girl and was already morphologically characterized in vitro and in vivo. We found that ROS formation and oxidative DNA damage were actually scarcely seen after irradiation of up to 30 Gy in these cells; that mitochondrial membrane potential was preserved; and that apoptotic changes were not demonstrated despite the relatively high-dose irradiation of 30 Gy. Therefore, the origin of the close similarity of radiosensitivity between adult articular chondrocytes and the human osteosarcoma cell line HS-Os-1, is considered to involve the low degree of ROS formation following irradiation; the similarity possibly results from the strong scavenging ability of these two kinds of cells for free radicals including hydroxyl radicals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964018

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  12 in total

1.  Development of a novel enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide for intratumoral injection for patients with low linear energy transfer-radioresistant neoplasms.

Authors:  Shiho Tokuhiro; Yasuhiro Ogawa; Kazuhiro Tsuzuki; Ryo Akima; Hironobu Ue; Shinji Kariya; Akihito Nishioka
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

2.  Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck.

Authors:  Stanley I Gutiontov; Zachary S Zumsteg; Benjamin H Lok; Sean Berry; Chiaojung J Tsai; Sean M McBride; Nadeem Riaz; Oren Cahlon; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2017-03-14

3.  Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.

Authors:  I Frank Ciernik; Andrzej Niemierko; David C Harmon; Wendy Kobayashi; Yen-Lin Chen; Torunn I Yock; David H Ebb; Edwin Choy; Kevin A Raskin; Norbert Liebsch; Francis J Hornicek; Thomas F Delaney
Journal:  Cancer       Date:  2011-03-29       Impact factor: 6.860

4.  Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II).

Authors:  Jiro Hitomi; Kei Kubota; Yasuhiro Ogawa; Norihiko Hamada; Yoriko Murata; Akihito Nishioka
Journal:  Exp Ther Med       Date:  2010-07-20       Impact factor: 2.447

5.  Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.

Authors:  Srinivasan Senthamizhchelvan; Robert F Hobbs; Hong Song; Eric C Frey; Zhe Zhang; Elwood Armour; Richard L Wahl; David M Loeb; George Sgouros
Journal:  J Nucl Med       Date:  2012-01-17       Impact factor: 10.057

6.  Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer.

Authors:  Akihito Nishioka; Yasuhiro Ogawa; Kana Miyatake; Michiko Tadokoro; Munenobu Nogami; Norihiko Hamada; Kei Kubota; Shinnji Kariya; Takuhiro Kohsaki; Toshiji Saibara; Takehiro Okabayashi; Kazuhiro Hanazaki
Journal:  Oncol Lett       Date:  2014-04-28       Impact factor: 2.967

Review 7.  Paradigm Shift in Radiation Biology/Radiation Oncology-Exploitation of the "H₂O₂ Effect" for Radiotherapy Using Low-LET (Linear Energy Transfer) Radiation such as X-rays and High-Energy Electrons.

Authors:  Yasuhiro Ogawa
Journal:  Cancers (Basel)       Date:  2016-02-25       Impact factor: 6.639

8.  Evaluation of Changes in Tumor Shadows and Microcalcifications on Mammography Following KORTUC II, a New Radiosensitization Treatment without any Surgical Procedure for Elderly Patients with Stage I and II Breast Cancer.

Authors:  Akira Tsuzuki; Yasuhiro Ogawa; Kei Kubota; Shiho Tokuhiro; Ryo Akima; Shin Yaogawa; Kenji Itoh; Yoko Yamada; Toshikazu Sasaki; Masahide Onogawa; Tomoaki Yamanishi; Shinji Kariya; Munenobu Nogami; Akihito Nishioka; Mitsuhiko Miyamura
Journal:  Cancers (Basel)       Date:  2011-09-09       Impact factor: 6.639

9.  Computed Tomography Demonstration of the Production and Distribution of Oxygen Gas Following Intratumoral Injection of a New Radiosensitizer (KORTUC) for Patients with Breast Cancer-Is Intratumoral Injection Not an Ideal Approach to Solve the Major Problem of Tumor Hypoxia in Radiotherapy?

Authors:  Naoya Hayashi; Yasuhiro Ogawa; Kei Kubota; Kazuhiro Okino; Ryo Akima; Shiho Morita-Tokuhiro; Akira Tsuzuki; Shin Yaogawa; Akihito Nishioka; Mitsuhiko Miyamura
Journal:  Cancers (Basel)       Date:  2016-04-01       Impact factor: 6.639

10.  Non-Surgical Breast-Conserving Treatment (KORTUC-BCT) Using a New Radiosensitization Method (KORTUC II) for Patients with Stage I or II Breast Cancer.

Authors:  Yasuhiro Ogawa; Kei Kubota; Nobutaka Aoyama; Tomoaki Yamanishi; Shinji Kariya; Norihiko Hamada; Munenobu Nogami; Akihito Nishioka; Masahide Onogawa; Mitsuhiko Miyamura
Journal:  Cancers (Basel)       Date:  2015-11-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.